JD HEALTH ADR Aktie

 

JD Health (06618.HK) announced that on April 1, 2026, pursuant to its post-IPO share award scheme, it granted 834,400 new award shares to grantees at a price of HKD48.64 per share, representing approximately 0.03% of the total issued shares.The company stated that the new grants aim to align the interests of the grantees with th......

According to the "JD Health Bulletin", JD Health (06618.HK) and Shouer Pharmaceutical recently signed an agreement to deepen their cooperation. The two parties will leverage JD Health's digital platform capabilities and supply chain advantages, combined with Shouer Pharmaceutical's extensive experience in the field of children's......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

JD HEALTH (06618.HK) had result beat throughout 1-4Q25, BofA Securities published a research report saying. Following the results, the broker hosted an investor meeting with the management. The Company is confident in further gaining a significant market share of the large pharmacy market. The strategy by category includes: 1) P......

JD HEALTH (06618.HK) announced its annual results yesterday, with quarterly results standing out, further proving that its strategy focusing on strengthening supply chain capabilities and user stickiness can continue to yield positive results, HSBC Global Research published a research report saying. The Group's competitive a......

JD HEALTH (06618.HK) achieved a revenue increase of 26.3% YoY last year, while its non-IFRS net profit reached RMB6.53 billion, corresponding to a profit margin of 8.9%, slightly exceeding market expectations, according to CICC's research report.CICC lowered its target price for JD HEALTH by 7% to HKD66.2 but kept the Outper......

JD HEALTH (06618.HK) announced its annual results for the year ended December 2025, with 4Q25 revenue growing 27% YoY, 4% above market consensus, according to Morgan Stanley's research report. Adjusted operating profit surged by 246% YoY, in line with expectation. Adjusted net profit rose by 30%, beating other income, but it......

According to Nomura's research report, JD HEALTH (06618.HK) saw a 28% YoY increase in 2H25 revenue, surpassing the market's and the broker's forecasts by 4% and 2%, respectively. Its non-IFRS operating profit margin also rose by 1.6 ppts to 5%, beating the broker's forecast by 0.3 ppts.In Nomura's calculation......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

JD HEALTH (06618.HK) announced its annual results ended December 2025. The revenue hiked 26.3% YoY to RMB73.441 billion. The net profit amounted to RMB5.375 billion, up 29.2%. EPS was RMB1.7. No dividend was declared.During the period, non-IFRS operating income increased by 68.9% YoY to RMB4.39 billion; and annual non-IFRS profi......

At close, HSI rose 71 pts or 0.3% to 25,321. HSTI dropped 33 pts or 0.7% to 4,796. HSCEI fell 32 pts or 0.4% to 8,451. Market turnover reached $321.87 billion.Active Heavyweights:BABA (09988.HK) closed at $126.3, down 2.8%MEITUAN (03690.HK) closed at $74.5, down 1.2%TENCENT (00700.HK) closed at $502, down 0.8%HKEX (00388.HK) clo......

~AASTOCKS Financial NewsWebsite: www.aastocks.com...

JD HEALTH (06618.HK) and ALI HEALTH (00241.HK) achieved strong revenue growth last year, with pharmaceutical sales increasing by 20-30%, significantly outperforming the national market's overall growth of only 2%, HSBC Global Research issued a research report saying. This reflects the continuous market share gain by online p......

CLSA released a research report expecting that JD HEALTH (06618.HK) will maintain its growth momentum in 2H25, driven by decent sales performance during Double 11 and a surge in flu inflections in December, with revenue increasing by 24.5% YoY to RMB37.1 billion. The broker continued to estimated that, supported by gross margin ......

JD HEALTH (06618.HK) announced that its JD Health Check-Up Center had formed a team of doctors, with 100% of them holding intermediate or higher professional titles. All doctors in the online service team are also associate senior or above, with chief doctors from key departments accounting for 22%.In addition, JD HEALTH will ap......

JD HEALTH (06618.HK) announced an in-depth collaboration with Beijing Peak Biology Pharmaceuticals (Peak Pharmaceutical) to jointly develop an integrated health management solution covering 'screening-diagnosis-treatment-medication-follow-up-protection.' This partnership aims to enhance the full-cycle health service layo......

JD HEALTH (06618.HK) has established an AI health service matrix, as the Securities Times learned from the "2026 JD Health Annual Doctor Festival". The "AI JD Doctor" system has more than 1,500 expert doctor AI agents online, and the industry's first full-scenario hospital large model product "JoyDoc......

At the 2026 JD Health Digital Intelligence Medical Conference, JD HEALTH (06618.HK), in collaboration with the First Affiliated Hospital of Wenzhou Medical University and the Key Laboratory of Clinical Nutrition and Intervention of China's National Health Commission (NHC), announced the release of an AI-driven full-process m......

JD HEALTH (06618.HK) has signed an agreement with multinational consumer health company Haleon to deepen their collaboration.Under the agreement, both parties aim to establish a comprehensive ecosystem for disease co-management and co-treatment by 2026, while expanding their cooperation from chronic disease management to over 15......

JD HEALTH (06618.HK) announced a deeper collaboration with multinational consumer health company, Haleon. The two parties will comprehensively build a new health service ecosystem for holistic disease co-management and co-governance, driving innovation from chronic disease management to full-cycle health management models. This ......